



## **Yoshiki Arakawa**

**Japan**

Professor Yoshiki Arakawa, M.D., Ph.D., is Chair in Department of Neurosurgery, Kyoto University Graduate School of Medicine. He has held various roles in Japanese & international physician associations, including in the Society for Neuro-Oncology (SNO), American Society of Clinical Oncology (ASCO), International Society of Paediatric Oncology (SIOP) & Asian Society for Neuro-Oncology (ASNO). His research interests include the molecular mechanism analysis of tumor initiation, progression, metastasis, & invasion, cancer virus therapy, tumor immunity, & pediatric glioma. He also served in several key clinical studies, such as Principal Investigator of A Randomized Phase III Study of Short-Course Radiotherapy Combined with Temozolomide in Elderly Patients with Newly Diagnosed Glioblastoma (AgedGlio-PIII, Japan Clinical Oncology Group (JCOG) 1910) and A Randomized Controlled Clinical Study of Radiotherapy Combined with Chemotherapy in Patients with Newly Diagnosed Central Nervous System Germ Cell Tumor (Japan Childhood Cancer Research Group (JCCG) CNSGCT2021).

### **Topic: MOA of TFields in GBM and Case Report**

Glioblastoma multiforme (GBM) is a devastating disease with poor prognosis. Optune, a portable device that administers Tumor Treating Fields (TFields), is the first therapy in over a decade to demonstrate a clinically and statistically significant improvement in overall survival in newly diagnosed GBM patients when added to temozolomide. As part of a NCCN Category 1 Preferred regimen in the NCCN Guidelines, Optune is an important tool in a physician's armamentarium in the management of GBM.

Optune is now available in Singapore.

In this symposium, our esteemed faculty share and discuss the published scientific and clinical data behind this unique treatment modality, as well as insights into their personal and institutional experience with Optune.